N-acetylcysteine for non-acetaminophen-induced acute liver failure

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized trial compares oral N-acetylcysteine plus standard supportive care to standard supportive care alone in adults with non-acetaminophen acute liver failure. Participants are 18 to 60 years old and are randomly assigned to receive NAC on a defined dosing schedule or to receive standard care, with outcomes assessed up to 28 days. The study looks at survival, liver function tests, and length of hospital stay as secondary outcomes. Conducted at King Edward Medical University and Mayo Hospital Lahore, the trial seeks to determine if NAC can improve outcomes in settings where liver transplantation is not readily available.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female, aged 18-60 years
* Diagnosed with non-acetaminophen- induced acute hepatic failure (per operational definition/EASL criteria)
* Etiology other than acetaminophen overdose (viral hepatitis HAV/HBV/HEV, non-acetaminophen drug-induced liver injury, or idiopathic)
* No NAC treatment received for current episode prior to enrollment

Exclusion Criteria:

* History of chronic liver disease or cirrhosis
* Prior severe cardiac, renal, neurological, or infectious disease that could confound outcomes
* Prior liver transplant or current transplant candidacy
* Known allergy/contraindication to NAC
* Pregnant women.

Where it's running

• King Edward Medical University/Mayo Hospital Lahore
  Lahore, Punjab Province, Pakistan Recruiting

Study contacts

• Principal investigator: Somia Iqtadar, FCPS — King Edward Medical University
• Study coordinator: Somia Iqtadar, FCPS
• Email: somia.iqtadar@gmail.com
• Phone: +92 42 99211129

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Reference framework for outcomes after machine-preserved liver transplantation in Europe

  This study tests how liver transplants that use machine perfusion perform in real-world practice, to see how different perfusion methods relate to outcomes for adults in Europe.

  Recruiting at 4 sites University Medical Center Groningen · Innsbruck and 37 other locations · NCT07585890

• Combined DPMAS (double plasma molecular adsorption) and therapeutic plasma exchange to improve clotting, reduce inflammation, and support organs in acute liver failure

  We will test whether combining DPMAS (double plasma molecular adsorption) with therapeutic plasma exchange (TPE) helps adults in the ICU with acute liver failure or acute-on-chronic liver failure recover organ function or safely reach a transplant.

  Recruiting Institute for Clinical and Experimental Medicine · Prague · NCT07329036

• Standard-volume versus high-volume plasma exchange for children with acute liver failure

  This trial will see if using high-volume plasma exchange instead of standard-volume plasma exchange helps children (ages 3–18) with acute liver failure keep their native liver.

  Recruiting Institute of Liver and Biliary Sciences, India · New Delhi, National Capital Territory of Delhi · NCT06831643

• F573 injection for treating liver injury and failure

  This study is testing if an injection called F573 can help people with liver injury or chronic hepatitis B feel better and recover.

  Recruiting at 10 sites Phase 2 Beijing Continent Pharmaceutical Co, Ltd. · Beijing, Beijing Municipality and 9 other locations · NCT05689645

• Registry for monitoring CytoSorb device use in critically ill patients

  This study is collecting information on how the CytoSorb device helps critically ill patients to improve care for conditions like septic shock and acute respiratory distress syndrome.

  Recruiting at 24 sites CytoSorbents, Inc · Klagenfurt and 27 other locations · NCT05146336

• Factors that affect how well mesenchymal stromal cell (MSC) therapy works for hepatitis B–related acute-on-chronic liver failure.

  This project will look back at people with hepatitis B–related ACLF who received MSC infusions to see which factors affect whether the treatment helps.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT07198854

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.